Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 10
Submit an article Journal homepage
146
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center

Miguel Arguello-Tomasa Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-3329-4151View further author information
ORCID Icon,
Nil Albiolb Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;e Hematology Department, Catalan Institute of Oncology (ICO), Hospital Universitari Doctor Josep Trueta, Girona, SpainORCID Iconhttps://orcid.org/0000-0003-2942-1362View further author information
ORCID Icon,
Paola Jarab Josep Carreras Leukemia Research Institute, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainView further author information
,
Irene Garcia-Cadenasa Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainView further author information
,
Sara Redondoa Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-8967-7410View further author information
ORCID Icon,
Albert Esquirola Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainView further author information
,
Silvana Novellia Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0001-8750-0195View further author information
ORCID Icon,
Silvana Saavedraa Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainView further author information
,
Rodrigo Martinoa Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainView further author information
,
Josep Nomdedeua Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainView further author information
,
Jordi Sierraa Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainView further author information
,
Alba Morad Sant Pau Institute for Biomedical Research, Barcelona, SpainView further author information
&
Carol Morenoa Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona;b Josep Carreras Leukemia Research Institute, Barcelona;c Medicine department, Universitat Autònoma de Barcelona, Barcelona;d Sant Pau Institute for Biomedical Research, Barcelona, SpainCorrespondence[email protected]
View further author information
 show all
Pages 1655-1661 | Received 24 Mar 2023, Accepted 27 Jun 2023, Published online: 15 Jul 2023

References

  • Albiol N, Arguello-Tomas M, Moreno C. The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. Curr Opin Oncol. 2021;33(6):670–680. doi:10.1097/CCO.0000000000000791
  • Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460–473. doi:10.1056/NEJMra1908213
  • Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–2437. doi:10.1056/NEJMoa1509388
  • Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. doi:10.1016/S1470-2045(18)30788-5
  • Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443. doi:10.1056/NEJMoa1817073
  • Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. doi:10.1056/NEJMoa1815281
  • Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291. doi:10.1016/S0140-6736(20)30262-2
  • Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33. doi:10.1016/j.annonc.2020.09.019
  • Wierda WG, Brown J, Abramson JS, et al. NCCN guidelines® insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 3.2022: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2022;20(6):622–634. doi:10.6004/jnccn.2022.0031
  • Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. doi:10.1182/blood-2017-09-806398
  • Burger JA, O'Brien S. Evolution of CLL treatment—from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15(8):510–527. doi:10.1038/s41571-018-0037-8
  • Ranti J, Perkonoja K, Kauko T, et al. Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center. eJHaem. 2022;3(1):291–300. doi:10.1002/jha2.322
  • Mato AR, Ghosh N, Sharman JP, et al. Real-world prognostic testing and treatment patterns in CLL/SLL: results from 1462 patients in the informCLL registry. Blood Adv. 2022;bloodadvances:2022008068.
  • Tam CS, Zhao F-L, Gauba R, et al. Population -wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset. HemaSphere. 2022;6:559–560. doi:10.1097/01.HS9.0000845528.50188.4f
  • Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–215. doi:10.1182/blood-2015-06-651125
  • Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the hospital clínic of Barcelona experience. Blood. 2009;114(10):2044–2050. doi:10.1182/blood-2009-04-214346
  • Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111(10):4916–4921. doi:10.1182/blood-2007-12-129379
  • Kajüter H, Wellmann I, Khil L, et al. Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany. Blood Cancer J. 2021;11(10):174. doi:10.1038/s41408-021-00556-7
  • Tam CS. Zanubrutinib versus Bendamustine and Rituximab in Untreated Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma (SEQUOIA): a Randomised, Controlled, Phase 3 Trial. 2022;23.
  • van der Straten L, Maas CCHM, Levin M-D, et al. Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in The Netherlands, 1989–2018. Blood Cancer J. 2022;12(4):72. doi:10.1038/s41408-022-00669-7

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.